J&J Profit Beats Estimates as CEO Sees More Deals to Fuel Growth

  • Pharma revenue rose with blockbuster Remicade, Stelara
  • J&J will continue to be active in M&A, CEO Gorsky says

J&J Earnings Tops Analysts' Estimates

Johnson & Johnson, the world’s largest health-care company, beat fourth-quarter profit estimates, helped by blockbusters like arthritis treatment Remicade and psoriasis drug Stelara.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.